In a research report published Monday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on bluebird bio (NASDAQ:BLUE) and raised his price …
In a research report released yesterday, Wedbush analyst David Nierengarten reiterated an Outperform rating on Bluebird Bio (NASDAQ:BLUE) with a price target of …
In a research report released Thursday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on bluebird bio Inc (NASDAQ:BLUE) with a price …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay initiated coverage on Bluebird Bio (NASDAQ:BLUE) with a Buy rating and a $50 price target, …
